雅各臣科研製藥(02633.HK)中期收益增加7.9% 純利達8290萬港元 中期息1.2港仙
格隆匯11月26日丨雅各臣科研製藥(02633.HK)發佈公吿,截至2021年9月30日止六個月,公司收益約為7.5億港元,同比增加約7.9%;溢利約為8290萬港元,較2020年同期的經調整溢利(不包括香港政府的一次性保就業計劃資助)上升約46.2%;中期股息每股普通股1.2港仙,總額約為2320萬港元。
儘管受疫情影響,集團非專利藥業務仍展現巨大韌性,於報吿期內錄得温和增長11.6%。此乃受到公營界別錄得9.3%的穩健增長以及私營界別顯著復甦,締造13.8%增幅所推動。
截至2021年9月30日,公司正在研發171項產品,其中54項已獲准註冊,10項已提交註冊,39項已完成開發階段並正進行穩定製備或穩定性研究,另有27項目前正進行配方研究或預製配方研究工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.